Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | TRHR | P34981 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853085 | 0.90 | SCN9A (0.42) | SCN9AFPR2TRHRCYP2C9TSHR | |
| SCHEMBL10102531 | 0.88 | SCN9A (0.46) | SCN9AFPR2TRHRCYP2C9TSHR | |
| SCHEMBL689785 | 0.88 | CPB2 (0.45) | SCN9ATRHRCPB2CPB1 | |
| SCHEMBL689786 | 0.88 | CPB2 (0.45) | SCN9ATRHRCPB2CPB1 | |
| SCHEMBL12980124 | 0.85 | SCN9A (0.41) | SCN9AFPR2TRHRCYP2C9TSHR | |
| SCHEMBL14886285 | 0.85 | SCN9A (0.41) | SCN9AFPR2TRHRCYP2C9TSHR | |
| SCHEMBL10122826 | 0.85 | SCN9A (0.43) | SCN9AFPR2TRHRCYP2C9TSHR | |
| SCHEMBL888805 | 0.85 | SCN9A (0.43) | SCN9AFPR2TRHRCYP2C9TSHR | |
| SCHEMBL22361422 | 0.84 | SCN9A (0.44) | SCN9AFPR2TRHRCYP2C9TSHR | |
| SCHEMBL19364688 | 0.83 | SCN9A (0.40) | SCN9AFPR2TRHRCPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8110583-B2 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-7893082-B2 | Antitumor agents; anticancer agents | MERCK PATENT GMBH (DE) | 2011-02-22 | — | — | US | disclosed |
| US-7868172-B2 | 2-(hetero)-aryl substituted tetrahydroquinoline derivatives | MERCK PATENT GMBH (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20090030028-A1 | Tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20080221118-A1 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080194615-A1 | Antitumor agents; anticancer agents | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20070203167-A1 | 2-(Hetero)-aryl substituted tetrahydrochinoline | MERCK PATENT GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030028-A1 | Tetrahydroquinolines | RECQL, QTRT1, NRAS | SCN9A 3976/4885FPR2 1732/4885TRHR 142/4885 |
| US-20070203167-A1 | 2-(Hetero)-aryl substituted tetrahydrochinoline | NCOR1, CCNT2, NCOR2 | SCN9A 4100/4885FPR2 1254/4885TRHR 58/4885 |
| US-20080194615-A1 | Antitumor agents; anticancer agents | RB1, TP53, CCNT1 | SCN9A 4510/4885FPR2 4364/4885TRHR 235/4885 |
| US-20080221118-A1 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | CCNE1, CCNA1, CCNT1 | SCN9A 4014/4885FPR2 2968/4885TRHR 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.